Targretin oral (bexarotene oral) News

12 3 4 5 6 7 8 9 10 »

|||||||||| IRX4204 / Io Therap, Targretin oral (bexarotene oral) / ReXceptor
Journal: Selective retinoid X receptor agonism promotes functional recovery and myelin repair in experimental autoimmune encephalomyelitis. (Pubmed Central) - Dec 21, 2024
These results inform the discovery of restorative neural therapeutics for MS by demonstrating that selective RXR agonism is sufficient for effective myelin repair. Moreover, our findings support the therapeutic potential of IRX4204 to promote functional recovery in MS.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Bexarotene ameliorated the pulmonary inflammation and M1 polarization of alveolar macrophages induced by cigarette smoke via PPAR?/HO-1. (Pubmed Central) - Dec 19, 2024
Moreover, our findings support the therapeutic potential of IRX4204 to promote functional recovery in MS. Our results indicated that bexarotene may curb inflammation and M1 polarization in COPD through activation of the PPAR?/HO-1 pathway.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: A structure-based approach to discover a potential isomerase Pin1 inhibitor for cancer therapy using computational simulation and biological studies. (Pubmed Central) - Dec 12, 2024
Finally, we inferred that residues K63, R68 and R69 are important in the binding process between bexarotene and Pin1. All in all, repurposing of FDA-approved drugs to inhibit Pin1 may provide a promising insight into the identification and development of new treatments for certain malignant tumors.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Review, Journal, IO biomarker: The LDL Receptor-Related Protein 1: Mechanisms and roles in promoting A? efflux transporter in Alzheimer's disease. (Pubmed Central) - Dec 12, 2024
deposition and ameliorate AD. Abbreviations: LRP1, LDL Receptor-Related Protein 1;LDL, Low Density Lipoprotein; A?, amyloid beta; AD, Alzheimer's disease; APP, amyloid precursor protein; ApoE, apolipoprotein E; TGF, growth factor; MMP, matrix metalloproteinase;TAT, thrombin-antithrombin complex; BBB, blood-brain barrier; MMP-9,cyclophilin A (CypA)-matrix metalloproteinase-9; VMC, Vascular Mural Cell; IDE,insulin degrading enzyme; EVs, extracellular vesicles; sLRP1,shed LRP1; BDNF, brain-derived neurotrophin; IGF-1,insulin-like growth factor 1; NGF, nerve growth factor; MAPK,mitogen-activated protein kinase; ERK1/2,exogenous signal-regulated kinase1/2;JNK, c-Jun amino-terminal kinase; TLR4, toll-like receptor 4; NF-?B,nuclear factor-?B; GCAP,guanylate cyclase-activating protein; KD, ketogenic diet;KB, ketone body; BLECs,Brain-like endothelial cell; BYHWD, Buyang Huanwu decoction; LGZG, Linguizhugan decoction;P- gp, P-glycoprotein;PPAR?, Peroxisome proliferator-activated receptor ?;SP16,SERPIN peptide 16; Asx, Astaxanthin; Bex, Bexarotene.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Preclinical, Journal: LncRNA DANCR suppresses acute myocardial infarction in mice via mediating p-RXRA/TRAF2/NIK/IKK/NF-?B signaling pathway. (Pubmed Central) - Dec 7, 2024
Abbreviations: LRP1, LDL Receptor-Related Protein 1;LDL, Low Density Lipoprotein; A?, amyloid beta; AD, Alzheimer's disease; APP, amyloid precursor protein; ApoE, apolipoprotein E; TGF, growth factor; MMP, matrix metalloproteinase;TAT, thrombin-antithrombin complex; BBB, blood-brain barrier; MMP-9,cyclophilin A (CypA)-matrix metalloproteinase-9; VMC, Vascular Mural Cell; IDE,insulin degrading enzyme; EVs, extracellular vesicles; sLRP1,shed LRP1; BDNF, brain-derived neurotrophin; IGF-1,insulin-like growth factor 1; NGF, nerve growth factor; MAPK,mitogen-activated protein kinase; ERK1/2,exogenous signal-regulated kinase1/2;JNK, c-Jun amino-terminal kinase; TLR4, toll-like receptor 4; NF-?B,nuclear factor-?B; GCAP,guanylate cyclase-activating protein; KD, ketogenic diet;KB, ketone body; BLECs,Brain-like endothelial cell; BYHWD, Buyang Huanwu decoction; LGZG, Linguizhugan decoction;P- gp, P-glycoprotein;PPAR?, Peroxisome proliferator-activated receptor ?;SP16,SERPIN peptide 16; Asx, Astaxanthin; Bex, Bexarotene. Studies demonstrated that DANCR suppressed AMI in mice by mediating p-RXRA/TRAF2/NIK/IKK/NF-?B pathway.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Review, Journal: Clinical characterization of mycosis fungoides with abnormal light reactions induced by narrow-band UVB therapy: A review of a single-center experience. (Pubmed Central) - Dec 2, 2024
Forty patients (30 men and 10 women) with MF (excluding patients treated with bexarotene or etretinate) who received NB-UVB therapy at the Department of Dermatology, University of Toyama, from January to December 2022 were analyzed...In addition, treatment can be continued by reducing the dose of NB-UVB or switching to a 308-nm excimer laser, even when ALR occurs. Accumulation of additional cases is required because there were only six patients with ALR in this study.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Synergistic Activation of VDR-RXR Heterodimers by Vitamin D and Rexinoids in Human Kidney and Brain Cells. (Pubmed Central) - Nov 27, 2024
Bexarotene (Bex) is an RXR ligand (rexinoid) developed to treat cutaneous T-cell lymphoma and is a putative therapeutic for other diseases...The results demonstrate a synergistic effect with both Bex and 1,25D which could be further modulated by (1) the protein levels (or polymorphic version) of VDR present in the cell, (2) the concentration of the ligands, (3) the cellular "background" (e.g., brain cells versus kidney cells), (4) the nature of the VDRE platform, or (5) the type of rexinoid (Bex analogs). Our findings suggest that diseases that respond to treatment with either vitamin D, or with rexinoids, may be amenable to enhanced therapeutic potential by employing multi-ligand dosing via combinatorial therapy.

|||||||||| fenretinide nanoparticle (ST-001 nanoFenretinide) / SciTech Development
First-in-Human Phase 1a Clinical Trial of the Investigational New Drug ST-001, a Novel Nano-Phospholipid Dispersion Formulation of Fenretinide, in Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (Halls G-H (San Diego Convention Center)) - Nov 21, 2024 - Abstract #ASH2024ASH_7228;
P1
Our findings suggest that diseases that respond to treatment with either vitamin D, or with rexinoids, may be amenable to enhanced therapeutic potential by employing multi-ligand dosing via combinatorial therapy. In a recently reported trial of intravenous fenretinide in hematologic malignancies, responses were reported in cutaneous T-cell lymphoma (CTCL) and angioimmunoblastic T-cell lymphoma (AITL) (Mohrbacher et al, PMID 28420721), including a sustained complete response in a S

|||||||||| Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin
Real-World Treatment Patterns in Patients with Mycosis Fungoides or S (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_6724;
P=N/A
Conclusions : This study showed the duration of mogamulizumab treatment (5.7 months) was similar in the real world compared to the results observed in the MAVORIC clinical trial (5.7 months). The duration of mogamulizumab treatment was longer in patients receiving combination treatment than those on monotherapy and warrants further investigation.

|||||||||| Folotyn (pralatrexate) / Aurobindo
Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_6691;
Conclusions Pralatrexate is effective and associated with durable responses in cytotoxic CTCL. Upon disease relapse, retreatment with pralatrexate was effective with high rates of second complete remissions observed in SPTCL.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Review, Journal: Role of Retinoids and Their Analogs in the Treatment of Cutaneous T-cell Lymphoma: A Systematic Review. (Pubmed Central) - Oct 15, 2024
In conclusion, the available studies and research have shown that retinoids play an important role in the mild and early stages of cutaneous T-cell lymphoma. However, further investigation is required to explain the mechanism of action of retinoids and the impact of their side effects in patients with cutaneous T-cell lymphoma.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Preclinical, Journal: Neuroprotective Effects of Bexarotene and Icariin in a Diabetic Rat Model. (Pubmed Central) - Sep 30, 2024
The lack of significant changes in BDNF and NfL suggests that longer study durations may be necessary to observe these effects. Future research should include extended study periods, larger sample sizes, varied dosages, and comprehensive behavioral assessments to better understand the therapeutic potential of these agents.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal, Myeloid-derived suppressor cells: Bexarotene Induce Differentiation of Myeloid-Derived Suppressor Cells through Arg-1 Signalling Pathway. (Pubmed Central) - Aug 31, 2024
Adoptive transfer of the induced MDSCs extended allograft survival. These results suggest that MDSCs can potentially be used in future clinical transplants to inhibit rejection, reduce adverse events, and induce operative tolerance.

|||||||||| Japanese regulatory, Journal: PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for myelofibrosis, bexarotene for adult T-cell leukemia/lymphoma, valemetostat for peripheral T-cell lymphoma, and pirtobrutinib for mantle cell lymphoma in Japan. (Pubmed Central) - Aug 26, 2024
These results suggest that MDSCs can potentially be used in future clinical transplants to inhibit rejection, reduce adverse events, and induce operative tolerance. No abstract available

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Targeting SEZ6L2 in Colon Cancer: Efficacy of Bexarotene and Implications for Survival. (Pubmed Central) - Aug 26, 2024
The study provides valuable insights into SEZ6L2 as a prognostic biomarker in colon cancer, revealing its intricate relationship with clinical parameters, treatment outcomes, and bexarotene effects. Context-dependent therapeutic responses emphasize the nuanced understanding required for SEZ6L2's role in colon cancer, paving the way for targeted therapeutic strategies.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Beta-amyloid regulates the microglial response to lipopolysaccharide via increasing APOE (MCP Hall A) - Aug 22, 2024 - Abstract #Neuroscience2024Neuroscience_1381;
was protective in unresolvable inflammation and APOE was a target to modulate inflammation during anti-A? therapy.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal, IO biomarker, Pan tumor, Machine learning: Multiomics and machine learning-based analysis of pancancer pseudouridine modifications. (Pubmed Central) - Aug 20, 2024
In conclusion, our work highlights the dysregulated features of PUSs and their role in the TME and patient prognosis, providing an initial molecular basis for future exploration of pseudouridine. Studies targeting pseudouridine are expected to lead to the development of potential diagnostic strategies and the evaluation and improvement of antitumor therapies.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal, Real-world evidence, Real-world: Real-world study on the use of pegylated interferon alpha-2a for treatment of mycosis fungoides/S (Pubmed Central) - Aug 14, 2024
PEG-IFN-?-2a for MF/SS resulted in an ORR of 53.3% and a mean (SD) TTNT of 9.2 (10.6) months. Combination regimens were superior to monotherapy and doses of 180?

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study. (Pubmed Central) - Aug 7, 2024
Bexarotene-induced hypertriglyceridemia showed positive bexarotene dose dependency and negative delta_FT4 dependency. Prophylactic and appropriate thyroid hormone compensation therapy and starting bexarotene at low doses with subsequent titration while managing dyslipidemia may have a beneficial effect for the successful continuation of bexarotene therapy without severe endocrine and metabolic AEs.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
The high-frequency ultrasonography patterns of the different skin lesions in mycosis fungoides. The case study. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3515;
We propose introducing a more precise tool for clinical staging assessment - HFUS. Our case confirms that HFUS is helpful in monitoring treatment effectiveness in MF as well as we revealed two patterns of HFUS pictures

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Prognostic factors for transformation in mycosis fungoides: series of 53 cases (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3152;
30,2% progressed to transformed MF with poor prognosis. Predictive factors statistically associated with disease progression and transformation were advanced stage (IIB, IIIA, IIIB, IVA) , age > 60 years, elevated serum LDH and rapid extension of skin lesions.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Unusual Presentation of Mycosis Fungoides: Multiple Subcutaneous Scalp Nodules (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3087;
Mycosis fungoides can present rare conditions as our case. Patients must be examined detailly in control visits, if abnormal signs detected apropriate imaging techniques and pathologic examination must be performed to accurate diagnosis and treatment.

|||||||||| Poteligeo (mogamulizumab-kpkc) / Kyowa Kirin, Targretin oral (bexarotene oral) / ReXceptor, Adcetris (brentuximab vedotin) / Takeda, Pfizer
The rare type of mycosis fungoides - case report (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3046;
After diagnostic examination and diagnosis of T cell lymphoma MF folliculotropic type, the patient was referred to the Center for Hematology, where combination chemotherapy of cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone (CHOEP) was administered, with predicted VI cycles. When treatments are timely and carried out in the less advanced stages of the disease, the progression of mycosis fungoides can be stopped, entering the remission when the clinical manifestations of the disease disappear.

|||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
a case of primary cutaneous anaplastic large cell lymphoma with excellent response to brentuximab (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_3001;
Patients with multifocal skin lesions and involvement of regional lymph nodes show a similar prognosis to those with cutaneous lesions alone. ALK-1 positivity is often positive in systemic ALCL and negative in pc-ALCL.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor, Rituxan (rituximab) / Roche
Therapeutic challenges in the treatmnet of calcinosis in autoimmune diseases. (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2459;
Here, we present a case of successful use of a method involving PRP and STS injections. Due to the fact that the beneficial effect of described above treatment among patients with dermatomyositis remains poorly documented in the literature, further research and standardization of the procedure are needed.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Preclinical, Journal: Exploring the combined therapeutic efficacy of bexarotene and icariin in type 2 diabetic rats. (Pubmed Central) - Jul 18, 2024
Icariin treatment exhibited robust antidiabetic effects with fewer side effects than other treatment options in this study. In future studies, long-term and varying doses of icariin will contribute to the development of novel antidiabetic drugs.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Rexinoids Induce Differential Gene Expression in Human Glioblastoma Cells and Protein-Protein Interactions in a Yeast Two-Hybrid System. (Pubmed Central) - Jul 16, 2024
Physiochemical analysis of the rexinoids reveals that the molecules cluster similarly to their gene expression patterns. Thus, rexinoids with similar RXR binding affinities drive differential gene expression by stimulating additional binding patterns in RXR and its homo- and heteropartners, driven by the physicochemical characteristics of these molecules.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Mycosis Fungoides Presenting With Multiple Tumors on the Face. (Pubmed Central) - Jun 27, 2024
Electron beam therapy (30 Gy in 10 fractions) applied to facial and plantar tumors resulted in a reduction of the tumors. This case highlights the treatment of tumors of MF on the face showing the effectiveness of combining electron beam therapy with bexarotene.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
The integration of epigenomic and transcriptomic sequencing data reveals cell-specific Bexarotene-induced transcriptional activity in APP/PS1 mouse brain (Exhibit (Pennsylvania Convention Center); In-Person) - Jun 19, 2024 - Abstract #AAIC2024AAIC_4528;
This case highlights the treatment of tumors of MF on the face showing the effectiveness of combining electron beam therapy with bexarotene. Results revealed that Bexarotene affected chromatin accessibility in microglia in correlation with Apoe expression.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas. (Pubmed Central) - Jun 2, 2024
Results revealed that Bexarotene affected chromatin accessibility in microglia in correlation with Apoe expression. Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Experience with bexarotene to treat cutaneous T-cell lymphomas: a study of the Spanish Working Group of Cutaneous Lymphomas. (Pubmed Central) - Jun 2, 2024
Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL. Our study confirms bexarotene is a safe and effective therapy for the long-term treatment of CTCL.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Biomarker, Journal: Simple Fluorescence Labeling Method Enables Detection of Intracellular Distribution and Expression Level of Retinoid X Receptors. (Pubmed Central) - May 15, 2024
Compound 4 is nonfluorescent, but the ether bond (-O-NBD) reacts with biothiols such as cysteine and homocysteine to generate a thioether (-S-NBD), followed by intramolecular Smiles rearrangement with an amino group such as that of lysine to form a fluorescent secondary amine (-NH-NBD) adjacent to the binding site. Fluorescence microscopy of intact or RXR-overexpressing MCF-7 cells after incubation with 4 enabled us to visualize RXR expression as well as nuclear transfer of RXR induced by the agonist bexarotene (1).

|||||||||| Targretin oral (bexarotene oral) / ReXceptor, cyclopamine / University of Macau
Journal, IO biomarker, Immune cell: Comprehensive analysis of exosome gene LYPD3 and prognosis/immune cell infiltration in lung cancer. (Pubmed Central) - Apr 15, 2024
LYPD3 is involved in many BPs of LC, such as regulating immune cell infiltration and affecting prognosis. Therefore, LYPD3 may have potential value as a biomarker for prognosis and immunotherapy in LC.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Evaluation of mortality, prognostic parameters, and treatment efficacy in mycosis fungoides. (Pubmed Central) - Apr 8, 2024
Our data support predictive validity of prognostic factors and models in MF and identified further potential parameters associated with poor survival. Prospective studies on prognostic indices across disease stages and treatment modalities are needed to predict and improve survival.

||||||||||  Targretin oral (bexarotene oral) / ReXceptor
Trial completion date, Trial primary completion date:  A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides (clinicaltrials.gov) -  Apr 4, 2024
P1, N=20, Recruiting,  Sponsor: Memorial Sloan Kettering Cancer Center
Prospective studies on prognostic indices across disease stages and treatment modalities are needed to predict and improve survival. Trial completion date: Mar 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

|||||||||| Cilcane (cilengitide) / Iceni Pharma, Jakafi (ruxolitinib) / Incyte, Targretin oral (bexarotene oral) / ReXceptor
Integrin ?V?3 activation by thyroid hormones triggers JAK/STAT oncogenic pathways that promote T cell lymphoma dissemination (Section 26) - Mar 5, 2024 - Abstract #AACR2024AACR_2541;
Although the FDA approved the use of inhibitors to target this pathway (Ruxolitinib), significant toxic effects have been reported and their use is limited...We found that THs induced STAT1, 3 and 5 phosphorylation in TCL cells and that the integrin ?V?3 inhibitor, Cilengitide (Cile) blunted these effects (p<0.05)...Finally, we evaluated the dissemination of TCL in an in vivo model (by vain tail) and found that BexT4+Cile reduced EL4 cell implantation into the liver and kidneys (p<0.05). These results described the mechanisms by which THs induce the activation of JAK/STAT oncogenic pathway and showed how the inhibition of integrin ?v?3 in combination with bexarotene has therapeutic potential for TCL.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Bexarotene leads to durable improvements in visual evoked potential latency: A follow-up study of the Cambridge Centre for Myelin Repair One trial. (Pubmed Central) - Mar 1, 2024
In an analysis of all eyes with recordable signal (24 bexarotene and 14 placebo), the adjusted bexarotene-placebo treatment difference in P100 latency was -7.79 (95% confidence interval (CI)?=?-14.76, -0.82) ms, p?=?0.044. We conclude that there were durable improvements in VEP latency, suggesting long-term benefits from exposure to a remyelinating drug.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor, Amnolake (tamibarotene) / Syros
Review, Journal: Retinoid Therapy for Neuroblastoma: Historical Overview, Regulatory Challenges, and Prospects. (Pubmed Central) - Feb 10, 2024
To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal, Metastases: Possible effects of plasminogen activator inhibitor-1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides. (Pubmed Central) - Feb 3, 2024
The serum levels of MMP-2 and MMP-9 was significantly increased in bexarotene non-responded patients compared to responded patients. Our present study suggested the significance of MMP-9 and PAI-1 for the progression of MF stage toward to the tumor stage, and could be a therapeutic target in future.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor, Tasigna (nilotinib) / Novartis, Inhibikase
Review, Journal: A common molecular and cellular pathway in developing Alzheimer and cancer. (Pubmed Central) - Jan 16, 2024
Innovative materials almost mutual mechanisms in the aetiology of cancer and AD advocates novel treatment approaches. Among these treatment strategies, the most promising use treatment such as tyrosine kinase inhibitor, nilotinib, protein kinase C, and bexarotene.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: A Biomimetic Multiparametric Assay to Characterise Anti-Amyloid Drugs. (Pubmed Central) - Dec 9, 2023
Such a well-adapted physico-chemical approach to drug discovery proves to be an undeniable asset for the rapid characterisation of compounds of therapeutic interest for Alzheimer's disease. This strategy could be adapted and transposed to search for modulators of other amyloids such as tau protein.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Review, Journal: Retinoid X receptor agonists as selective modulators of the immune system for the treatment of cancer. (Pubmed Central) - Dec 4, 2023
Bexarotene is the first successful example of an effective therapeutic that molecularly targets RXR; this drug was approved to treat cutaneous T cell lymphoma and is still used as a standard of care treatment for this disease...In this review, we provide an overview of the multiple mechanisms by which RXR signaling regulates inflammation and tumor immunity. We also discuss the potential of RXR-dependent immune cell modulation for the treatment or prevention of cancer and concomitant challenges and opportunities.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas. (Pubmed Central) - Nov 14, 2023
This work broadens our understanding of RXR-ligand relationships and permits development of possibly more efficacious pharmaceutical drugs. Modifications of RXR agonists can yield agents with enhanced biological selectivity and potency when compared to the parent compound, potentially leading to improved patient outcomes.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Journal: Identification of metabolism terms significantly affecting hepatocellular carcinoma immune microenvironment and immunotherapy response. (Pubmed Central) - Nov 9, 2023
Furthermore, through the use of LASSO logistic regression analysis, we identified 19 characteristic genes, which could robustly indicate the risk groups. Our research underscores the role of linoleic acid metabolism, sphingolipid metabolism and the regulation of lipolysis in adipocytes in HCC, pointing towards potential avenues for future research.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor, Vistide (cidofovir) / Gilead
Journal: Molecular docking analysis of HSV-1 proteins models with synthetic and plant derived compounds. (Pubmed Central) - Nov 6, 2023
Hence, the ligand protein interaction of the US9, UL20, and gH protein models were carried out with synthetic drugs like acyclovir, bexarotene, vinorelbine, foscarnet, famciclovir, cidofovir and two plant derived natural drug acacetin and anthraquinone. Based on structure and docking study, it is predicted that protein US20 and gH binds with particular anti-HSV drug i.e. acyclovir, cidofovir, acacetin and famciclovir, acacetin respectively, while interaction of different protein is different with drugs.

|||||||||| Adcetris (brentuximab vedotin) / Seagen, Takeda
Clinical data, Journal, HEOR, Real-world evidence, Real-world: Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States. (Pubmed Central) - Nov 5, 2023
Based on structure and docking study, it is predicted that protein US20 and gH binds with particular anti-HSV drug i.e. acyclovir, cidofovir, acacetin and famciclovir, acacetin respectively, while interaction of different protein is different with drugs. These real-world outcomes are consistent with ALCANZA results, demonstrating favorable outcomes with BV vs. OST in patients with CTCL previously treated with ?1 systemic therapy.

|||||||||| Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, metformin / Generic mfg., Targretin oral (bexarotene oral) / ReXceptor
Journal: Design, synthesis and characterization of a novel multicomponent salt of bexarotene with metformin and application in ameliorating psoriasis with T2DM. (Pubmed Central) - Nov 3, 2023
In a mouse model of imiquimod-induced psoriasis with T2DM, MET-BEX ameliorated imiquimod-induced psoriasis morphological features and systematic inflammation and improved glucolipid metabolism. These results showed that the multicomponent drug combination strategy in this study optimized the physicochemical properties of MET and BEX simultaneously, providing a promising candidate therapy for psoriasis with T2DM.

|||||||||| Targretin oral (bexarotene oral) / ReXceptor
Single-cell transcriptional and chromatin architecture changes in response to bexarotene-activated nuclear RXR in the brain of APP/PS1 mice (WCC Halls A-C) - Nov 3, 2023 - Abstract #Neuroscience2023NEUROSCIENCE_12815;
trafficking. We also show bexarotene-mediated transcriptional responses in brain barriers.

||||||||||  Targretin oral (bexarotene oral) / ReXceptor
Trial completion date, Trial primary completion date, Metastases:  The Role of Bexarotene in Inducing Susceptibility to Chemotherapy in Metastatic TNBC (clinicaltrials.gov) -  Oct 11, 2023
P1, N=12, Recruiting,  Sponsor: National Cancer Centre, Singapore
We also show bexarotene-mediated transcriptional responses in brain barriers. Trial completion date: Jun 2023 --> Sep 2025 | Trial primary completion date: Jun 2023 --> Sep 2024

|||||||||| Zarnestra (tipifarnib) / Kura Oncology, Targretin oral (bexarotene oral) / ReXceptor
Biomarker, Journal, IO biomarker: RAD51AP1 as an Immune-Related Prognostic Biomarker and Therapeutic Response Predictor in Hepatocellular Carcinoma. (Pubmed Central) - Oct 4, 2023
It may be related to the immunosuppressive microenvironment and could be an underlying HCC treatment strategy. However, the conclusions still require further validation studies.



	Diseases Companies Products Productz Mechanisms of Action Sites